De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
Harvard Bioscience Beheer
Beheer criteriumcontroles 1/4
De CEO Harvard Bioscience's is Jim Green, benoemd in Jul2019, heeft een ambtstermijn van 5.25 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 2.39M, bestaande uit 24.5% salaris en 75.5% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 4.38% van de aandelen van het bedrijf, ter waarde $ 5.13M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 2 jaar en 7 jaar.
Belangrijke informatie
Jim Green
Algemeen directeur
US$2.4m
Totale compensatie
| Percentage CEO-salaris | 24.5% |
| Dienstverband CEO | 5.3yrs |
| Eigendom CEO | 4.4% |
| Management gemiddelde ambtstermijn | 2yrs |
| Gemiddelde ambtstermijn bestuur | 7yrs |
Recente managementupdates
Recent updates
Harvard Bioscience (NASDAQ:HBIO) Is Making Moderate Use Of Debt
Aug 07
Harvard Bioscience, Inc.'s (NASDAQ:HBIO) Shares Not Telling The Full Story
Jul 15Even With A 25% Surge, Cautious Investors Are Not Rewarding Harvard Bioscience, Inc.'s (NASDAQ:HBIO) Performance Completely
Dec 22Harvard Bioscience, Inc.'s (NASDAQ:HBIO) Intrinsic Value Is Potentially 60% Above Its Share Price
Sep 23Harvard Bioscience, Inc. (NASDAQ:HBIO) Stock's 25% Dive Might Signal An Opportunity But It Requires Some Scrutiny
Aug 10An Intrinsic Calculation For Harvard Bioscience, Inc. (NASDAQ:HBIO) Suggests It's 23% Undervalued
Apr 26Here's Why Harvard Bioscience (NASDAQ:HBIO) Can Afford Some Debt
Apr 11Harvard Bioscience GAAP EPS of $0.05 beats by $0.06, revenue of $29.2M misses by $1.2M
Aug 04Harvard Bioscience (NASDAQ:HBIO) Takes On Some Risk With Its Use Of Debt
Jun 08Harvard Bioscience - Dressed Up And Waiting For A Suitor
Mar 15Here's Why Harvard Bioscience (NASDAQ:HBIO) Can Manage Its Debt Responsibly
Feb 16Is Harvard Bioscience (NASDAQ:HBIO) Using Too Much Debt?
Nov 04Is Harvard Bioscience, Inc. (NASDAQ:HBIO) Trading At A 37% Discount?
Oct 01An Intrinsic Calculation For Harvard Bioscience, Inc. (NASDAQ:HBIO) Suggests It's 25% Undervalued
May 04These 4 Measures Indicate That Harvard Bioscience (NASDAQ:HBIO) Is Using Debt Extensively
Apr 19Analysts Are Optimistic We'll See A Profit From Harvard Bioscience, Inc. (NASDAQ:HBIO)
Apr 04Have Insiders Sold Harvard Bioscience, Inc. (NASDAQ:HBIO) Shares Recently?
Mar 20What Kind Of Shareholders Hold The Majority In Harvard Bioscience, Inc.'s (NASDAQ:HBIO) Shares?
Mar 07Harvard Bioscience (NASDAQ:HBIO) Shareholders Have Enjoyed A 92% Share Price Gain
Feb 17An Intrinsic Calculation For Harvard Bioscience, Inc. (NASDAQ:HBIO) Suggests It's 35% Undervalued
Feb 02
Have Insiders Been Buying Harvard Bioscience, Inc. (NASDAQ:HBIO) Shares This Year?
Jan 15Harvard Bioscience: Wait For The Green Shoots Of Improvement
Jan 12Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$11m |
| Mar 31 2024 | n/a | n/a | -US$9m |
| Dec 31 2023 | US$2m | US$586k | -US$3m |
| Sep 30 2023 | n/a | n/a | -US$3m |
| Jun 30 2023 | n/a | n/a | -US$5m |
| Mar 31 2023 | n/a | n/a | -US$2m |
| Dec 31 2022 | US$2m | US$574k | -US$10m |
| Sep 30 2022 | n/a | n/a | -US$7m |
| Jun 30 2022 | n/a | n/a | -US$4m |
| Mar 31 2022 | n/a | n/a | -US$6m |
| Dec 31 2021 | US$3m | US$574k | -US$288k |
| Sep 30 2021 | n/a | n/a | -US$2m |
| Jun 30 2021 | n/a | n/a | -US$3m |
| Mar 31 2021 | n/a | n/a | -US$4m |
| Dec 31 2020 | US$3m | US$574k | -US$8m |
| Sep 30 2020 | n/a | n/a | -US$7m |
| Jun 30 2020 | n/a | n/a | -US$8m |
| Mar 31 2020 | n/a | n/a | -US$7m |
| Dec 31 2019 | US$3m | US$265k | -US$5m |
| Sep 30 2019 | n/a | n/a | -US$2m |
| Jun 30 2019 | n/a | n/a | US$432k |
| Mar 31 2019 | n/a | n/a | -US$819k |
| Dec 31 2018 | US$153k | n/a | -US$4m |
| Sep 30 2018 | n/a | n/a | -US$8m |
| Jun 30 2018 | n/a | n/a | -US$8m |
| Mar 31 2018 | n/a | n/a | -US$7m |
| Dec 31 2017 | US$129k | n/a | -US$2m |
Compensatie versus markt: De totale vergoeding ($USD 2.39M ) Jim } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 667.78K ).
Compensatie versus inkomsten: De vergoeding van Jim is gestegen terwijl het bedrijf verliesgevend is.
CEO
Jim Green (66 yo)
5.3yrs
Tenure
US$2,392,240
Compensatie
Mr. James W. Green, also known as Jim, has been the Chairman of Harvard Bioscience, Inc. since June 5, 2017 and its Director since April 30, 2015. He serves as President and Chief Executive Officer of Harv...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| President | 5.3yrs | US$2.39m | 4.38% $ 4.6m | |
| CFO & Treasurer | 1.8yrs | US$571.27k | 0.097% $ 101.1k | |
| Chief Legal Counsel & Corporation Secretary | 2.2yrs | geen gegevens | geen gegevens | |
| Senior Vice President of Global Sales | 1.4yrs | geen gegevens | geen gegevens | |
| Vice President of Global People Operations | no data | geen gegevens | geen gegevens | |
| Corporate Controller | no data | geen gegevens | geen gegevens | |
| Director of Corporate Accounting & SEC Reporting | no data | geen gegevens | geen gegevens |
2.0yrs
Gemiddelde duur
63yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van HBIO wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 2 jaar), wat duidt op een nieuw team.
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| President | 9.5yrs | US$2.39m | 4.38% $ 4.6m | |
| Independent Director | 5.1yrs | US$213.09k | 0.52% $ 547.3k | |
| Lead Independent Director | 9.9yrs | US$223.06k | 1.15% $ 1.2m | |
| Independent Director | 7yrs | US$205.45k | 0.57% $ 598.7k | |
| Independent Director | 7yrs | US$198.09k | 0.61% $ 636.6k |
7.0yrs
Gemiddelde duur
58yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van HBIO wordt beschouwd als ervaren (gemiddelde ambtstermijn 7 jaar).